Literature DB >> 7686600

Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease.

E Göker1, J T Lin, T Trippett, Y Elisseyeff, W P Tong, D Niedzwiecki, C Tan, P Steinherz, B I Schweitzer, J R Bertino.   

Abstract

We compared blast cells from adult and pediatric patients with untreated acute lymphoblastic leukemia (ALL) (as separated groups of T-lineage cell and B-lineage cell ALL) to determine if methotrexate (MTX) polyglutamate formation in adult patients might be a contributing cause to the known difference in clinical outcome, since MTX is a key drug in chemotherapy regimens. Adult B-lineage cell ALL blasts and blasts from the patients with T-lineage cell ALL accumulated lower amounts of total MTX and polyglutamates, especially long-chain MTX polyglutamates (glu3-6) than pediatric B-lineage cell ALL blasts. In view of the importance of polyglutamylation of MTX as a determinant of cytotoxicity of this drug, decreased formation of MTX polyglutamates is likely a contributing cause to the lower cure rate in adult ALL and T-lineage cell ALL as compared to childhood B-lineage cell ALL.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7686600

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  8 in total

Review 1.  Molecular pharmacodynamics in childhood leukemia.

Authors:  R Pieters; M L den Boer
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

2.  Phase II trial of oral aminopterin for adults and children with refractory acute leukemia.

Authors:  Peter D Cole; Richard A Drachtman; Angela K Smith; Sarah Cate; Richard A Larson; Douglas S Hawkins; John Holcenberg; Kara Kelly; Barton A Kamen
Journal:  Clin Cancer Res       Date:  2005-11-15       Impact factor: 12.531

3.  Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404).

Authors:  Barbara L Asselin; Meenakshi Devidas; Chenguang Wang; Jeanette Pullen; Michael J Borowitz; Robert Hutchison; Steven E Lipshultz; Bruce M Camitta
Journal:  Blood       Date:  2011-04-07       Impact factor: 22.113

4.  Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.

Authors:  Vinod Pullarkat; Marilyn L Slovak; Kenneth J Kopecky; Stephen J Forman; Frederick R Appelbaum
Journal:  Blood       Date:  2007-12-21       Impact factor: 22.113

5.  Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.

Authors:  E Masson; M V Relling; T W Synold; Q Liu; J D Schuetz; J T Sandlund; C H Pui; W E Evans
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

6.  Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia.

Authors:  T W Synold; M V Relling; J M Boyett; G K Rivera; J T Sandlund; H Mahmoud; W M Crist; C H Pui; W E Evans
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

7.  Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models.

Authors:  G W Aherne; E Ward; N Lawrence; D Dobinson; S J Clarke; H Musgrove; F Sutcliffe; T Stephens; A L Jackman
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

8.  Binding of a Smad4/Ets-1 complex to a novel intragenic regulatory element in exon12 of FPGS underlies decreased gene expression and antifolate resistance in leukemia.

Authors:  Shachar Raz; Michal Stark; Yehuda G Assaraf
Journal:  Oncotarget       Date:  2014-10-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.